AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6392353 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular levonantradol 1.0 mg
Number of subjects: 20
Study 6392353 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular levonantradol 1.5 mg
Number of subjects: 20
Study 6392353 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular levonantradol 2.0 mg
Number of subjects: 20
Study 6392353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31059641 — intervention group
Group type: EXPERIMENTAL
Intervention: HTTRx (10 mg)
Number of subjects: 46
Study 31059641 — intervention group
Group type: EXPERIMENTAL
Intervention: HTTRx (30 mg)
Number of subjects: 46
Study 31059641 — intervention group
Group type: EXPERIMENTAL
Intervention: HTTRx (60 mg)
Number of subjects: 46
Study 31059641 — intervention group
Group type: EXPERIMENTAL
Intervention: HTTRx (90 mg)
Number of subjects: 46
Study 31059641 — intervention group
Group type: EXPERIMENTAL
Intervention: HTTRx (120 mg)
Number of subjects: 46
Study 31059641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 28578601 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (300 mg twice daily)
Number of subjects: 302
Study 28578601 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (single-agent chemotherapy of physician's choice)
Number of subjects: 302
Study 25835109 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 µg ramosetron
Number of subjects: 12
Study 25835109 — intervention group
Group type: COMPARATOR
Intervention: Test meal alone
Number of subjects: 12
Study 24251677 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes prevention program (7 interactive classes and behavioral support)
Number of subjects: 67
Study 24251677 — intervention group
Group type: COMPARATOR
Intervention: Enhanced standard care (2 interactive classes on diabetes prevention)
Number of subjects: 67
Study 24251677 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 67
Study 22940687 — intervention group
Group type: COMPARATOR
Intervention: Control group (N=245)
Number of subjects: 245
Study 19230737 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaglucan-enriched bread (3g/day)
Number of subjects: 46
Study 19230737 — intervention group
Group type: COMPARATOR
Intervention: White bread without betaglucan
Number of subjects: 46
Study 17129592 — intervention group
Group type: COMPARATOR
Intervention: GSK albendazole
Number of subjects: 1277
Study 17129592 — intervention group
Group type: COMPARATOR
Intervention: Royal Drug albendazole
Number of subjects: 1277
Study 17129592 — intervention group
Group type: EXPERIMENTAL
Intervention: Curex albendazole
Number of subjects: 1277
Study 14695734 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amantadine
Number of subjects: 24
Study 14695734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 15892278 — intervention group
Group type: EXPERIMENTAL
Intervention: Gufusheng capsule (GFSC) combined with arthrectomy hip synovial membrane excision, femoral head decompression, and muscle-bone flap transplantation
Number of subjects: 45
Study 15892278 — intervention group
Group type: COMPARATOR
Intervention: Arthrectomy hip synovial membrane excision, femoral head decompression, and muscle-bone flap transplantation (Control)
Number of subjects: 45
Study 10336032 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral tarsorrhaphy
Number of subjects: 36
Study 10336032 — intervention group
Group type: COMPARATOR
Intervention: Tight patching
Number of subjects: 36
Study 8598699 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued second-line therapy (n = 142)
Number of subjects: 285
Study 8598699 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 143)
Number of subjects: 285
Study 1662127 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose of 300 mg on the first day and 150 mg for the subsequent 5 days (Group 1)
Number of subjects: 23
Study 1662127 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose of 400 mg on the first day and 200 mg for the subsequent 5 days (Group 2)
Number of subjects: 23
Study 6123123 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg cloxazolam
Number of subjects: 144
Study 6123123 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg diazepam
Number of subjects: 144
Study 6123123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 31375753 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Alternate-day Calorie Restriction (MACR)
Number of subjects: 43
Study 31375753 — intervention group
Group type: COMPARATOR
Intervention: Normal habitual diet (Control)
Number of subjects: 43
Study 29645317 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow infusion (SI) of low-dose ketamine (0.3 mg/kg)
Number of subjects: 59
Study 29645317 — intervention group
Group type: COMPARATOR
Intervention: Intravenous push (IVP) of low-dose ketamine (0.3 mg/kg)
Number of subjects: 59
Study 26781417 — intervention group
Group type: EXPERIMENTAL
Intervention: air+resveratrol
Number of subjects: 0
Study 26781417 — intervention group
Group type: EXPERIMENTAL
Intervention: hyperoxia+resveratrol
Number of subjects: 0
Study 26781417 — intervention group
Group type: COMPARATOR
Intervention: hyperoxia
Number of subjects: 0
Study 26781417 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 0
Study 24213962 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity blue light therapy (λmax = 465 nm, 84.8 µW/cm(2), 39.5 lux, 1.74 × 10(14) photons/cm(2)/s)
Number of subjects: 30
Study 24213962 — intervention group
Group type: COMPARATOR
Intervention: Lower-intensity yellow light therapy (λmax = 574 nm, 18.5 µW/cm(2), 68 lux, 1.21 × 10(12) photons/cm(2)/s)
Number of subjects: 30
Study 24213962 — intervention group
Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 30
Study 22947842 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete oral prophylaxis (periodontal therapy)
Number of subjects: 40
Study 20660892 — intervention group
Group type: EXPERIMENTAL
Intervention: Thought suppression during Week 2
Number of subjects: 0
Study 20660892 — intervention group
Group type: EXPERIMENTAL
Intervention: Thought expression during Week 2
Number of subjects: 0
Study 20660892 — intervention group
Group type: COMPARATOR
Intervention: Control group (no thought suppression or expression) during Week 2
Number of subjects: 0
Study 17986818 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term psychosocial intervention programme for family carers, including education about dementia and structured problem-solving in 6 group meetings.
Number of subjects: 180
Study 17986818 — intervention group
Group type: COMPARATOR
Intervention: Control group received treatment as usual.
Number of subjects: 180
Study 17986818 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term psychosocial intervention programme for family carers.
Number of subjects: 180
Study 16291984 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 20 mg
Number of subjects: 278
Study 16291984 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 40 mg
Number of subjects: 278
Study 16291984 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 80 mg
Number of subjects: 278
Study 16291984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study 16291984 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (one year treatment)
Number of subjects: 278
Study 11889322 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK solution (30% glucose in water with insulin 50 IU/L, and KCl 40 mM) at 1.5 mL/kg/hr for 24 hrs
Number of subjects: 20
Study 11889322 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline) at 1.5 mL/kg/hr for 24 hrs
Number of subjects: 20
Study 11889322 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 healthy volunteers with no heart disease)
Number of subjects: 20
Study 11783297 — intervention group
Group type: EXPERIMENTAL
Intervention: Gandou I (GD)
Number of subjects: 94
Study 11783297 — intervention group
Group type: COMPARATOR
Intervention: Dimercaptosuccinate acid (DMSA)
Number of subjects: 94
Study 7604142 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 41
Study 7604142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 31815542 — intervention group
Group type: EXPERIMENTAL
Intervention: Extravirgin olive oil consumption
Number of subjects: 0
Study 31815542 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 0
Study 28763898 — intervention group
Group type: EXPERIMENTAL
Intervention: Single lumen endobronchial tube (D group, n=30)
Number of subjects: 60
Study 28763898 — intervention group
Group type: COMPARATOR
Intervention: Double lumen endobronchial tube (S group, n=30)
Number of subjects: 60
Study 26140898 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator training (SIM)
Number of subjects: 19
Study 24081996 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette brand logo awareness
Number of subjects: 2423
Study 24081996 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and household tobacco use
Number of subjects: 2423
Study 21591581 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (10 microg/kg body weight) for five consecutive days
Number of subjects: 16
Study 21591581 — intervention group
Group type: COMPARATOR
Intervention: Placebo for five consecutive days
Number of subjects: 16
Study 17389264 — intervention group
Group type: EXPERIMENTAL
Intervention: LVH[-] group
Number of subjects: 73
Study 17389264 — intervention group
Group type: EXPERIMENTAL
Intervention: LVH[+] group
Number of subjects: 73
Study 17389264 — intervention group
Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 73
Study 17389264 — intervention group
Group type: EXPERIMENTAL
Intervention: LVH[-] and LVH[+] groups
Number of subjects: 73
Study 15731121 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tacrolimus 0.1%
Number of subjects: 4186
Study 15731121 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tacrolimus 0.03%
Number of subjects: 4186
Study 15731121 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical pimecrolimus
Number of subjects: 4186
Study 15731121 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical pimecrolimus and tacrolimus
Number of subjects: 4186
Study 15731121 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 4186
Study 12018715 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (1 g IV for 3 days in weeks 1 and 2, 2 days in week 3, 1 day in week 4)
Number of subjects: 18
Study 12018715 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisone (1.5 mg/kg/day for 4 weeks)
Number of subjects: 18
Study 10638398 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg DHEM/2% RAMEB nasal spray
Number of subjects: 9
Study 10638398 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg DHEM/4 mg RAMEB nasal powder
Number of subjects: 9
Study 10638398 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg Diergo nasal spray
Number of subjects: 9
Study 10638398 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg DHEM solution p.o.
Number of subjects: 9
Study 10638398 — intervention group
Group type: COMPARATOR
Intervention: i.m. administration of 0.5 mg DHEM
Number of subjects: 9
Study 7501485 — intervention group
Group type: EXPERIMENTAL
Intervention: Special Care Unit (SCU)
Number of subjects: 220
Study 7501485 — intervention group
Group type: COMPARATOR
Intervention: Intensive Care Unit (ICU)
Number of subjects: 220
Study 1904351 — intervention group
Group type: EXPERIMENTAL
Intervention: rtPA
Number of subjects: 33
Study 1904351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 6753183 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol followed by fructose
Number of subjects: 10
Study 6753183 — intervention group
Group type: COMPARATOR
Intervention: Alcohol followed by placebo
Number of subjects: 10
Study 30696454 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 24
Study 30696454 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 24
Study 30696454 — intervention group
Group type: COMPARATOR
Intervention: No exercise
Number of subjects: 24
Study 30672233 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with Betastatin mesylate (12 mg, 3 times a day) and mecobalamin (0.5 mg, 3 times a day)
Number of subjects: 96
Study 30672233 — intervention group
Group type: COMPARATOR
Intervention: Simple western medication (Betastatin mesylate 12 mg, 3 times a day and mecobalamin 0.5 mg, 3 times a day)
Number of subjects: 96
Study 27006007 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention for antenatal anxiety led by midwives
Number of subjects: 0
Study 27006007 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention for antenatal anxiety
Number of subjects: 0
Study 25051294 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in salivary estradiol levels
Number of subjects: 62
Study 23039913 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT) group training
Number of subjects: 162
Study 19830574 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial dynamic magnetotherapy (TcDMT)
Number of subjects: 54
Study 19830574 — intervention group
Group type: COMPARATOR
Intervention: Basal therapy
Number of subjects: 54
Study 17646490 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified form with improved readability and processability
Number of subjects: 190
Study 17646490 — intervention group
Group type: COMPARATOR
Intervention: Standard form
Number of subjects: 190
Study 17646490 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified form
Number of subjects: 190
Study 16243716 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme extract (900 mg) in three divided doses
Number of subjects: 21
Study 16243716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 16243716 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme therapy
Number of subjects: 21
Study 11857598 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminolaevulinic acid (ALA) 60 mg/kg BW, oral, 6-8 hours prior to PDT
Number of subjects: 40
Study 11857598 — intervention group
Group type: COMPARATOR
Intervention: Photosan 2 mg/kg BW, i.v., 48 hours before PDT
Number of subjects: 40
Study 10459544 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (FK)
Number of subjects: 20
Study 10459544 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CSA)
Number of subjects: 20
Study 8520561 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (ChT) plus radiotherapy (RT)
Number of subjects: 124
Study 8520561 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (ChT) alone
Number of subjects: 124
Study 8520561 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who achieved complete response (CR) after treatment
Number of subjects: 124
Study 8520561 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who achieved partial response (PR) after induction ChT
Number of subjects: 124
Study 2215254 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame-sweetened beverage (600 mg APM per serving)
Number of subjects: 6
Study 2215254 — intervention group
Group type: COMPARATOR
Intervention: Unsweetened beverage
Number of subjects: 6
Study 77367 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cromoglycate
Number of subjects: 20
Study 77367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31842259 — intervention group
Group type: EXPERIMENTAL
Intervention: FunctionalHIIT
Number of subjects: 20
Study 31842259 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 20
Study 28746262 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Arm I
Number of subjects: 43
Study 28746262 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Arm II
Number of subjects: 43
Study 28746262 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 43
Study 27473440 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured lifestyle intervention over 12 months including individualized endurance training (minimum of 18 MET-h physical activity per week) and nutrition education based on the Mediterranean diet.
Number of subjects: 600
Study 27473440 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group) receiving information regarding a healthy lifestyle.
Number of subjects: 600
Study 27473440 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured lifestyle intervention group (IG) with monthly group training sessions and regular telephone contacts.
Number of subjects: 600
Study 27473440 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) receiving one general training session about healthy nutrition.
Number of subjects: 600
Study 27473440 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment at randomization and subsequent time points (3 and 12 months) using spiroergometry and validated questionnaires.
Number of subjects: 600
Study 25162191 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief cognitive behavioral therapy (3 weeks, 6 sessions)
Number of subjects: 80
Study 25162191 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 80
Study 22726532 — intervention group
Group type: EXPERIMENTAL
Intervention: MDFR + Text Messages + Dietary Feedback
Number of subjects: 0
Study 22726532 — intervention group
Group type: EXPERIMENTAL
Intervention: MDFR + Dietary Feedback
Number of subjects: 0
Study 22726532 — intervention group
Group type: COMPARATOR
Intervention: MDFR, no feedback
Number of subjects: 0
Study 20708570 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive classroom curriculum program, enhancements to school climate, improvements in care pathways, and community forums.
Number of subjects: 5633
Study 20708570 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparison group)
Number of subjects: 5633
Study 20708570 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher-rated assessments of school climate.
Number of subjects: 5633
Study 17482623 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg daily for 4 weeks, increasing to 45 mg for 12 weeks
Number of subjects: 22
Study 16130888 — intervention group
Group type: EXPERIMENTAL
Intervention: Consulting physicians
Number of subjects: 3139
Study 16130888 — intervention group
Group type: EXPERIMENTAL
Intervention: Taking OTC medication
Number of subjects: 3139
Study 16130888 — intervention group
Group type: EXPERIMENTAL
Intervention: Doing nothing
Number of subjects: 3139
Study 16130888 — intervention group
Group type: EXPERIMENTAL
Intervention: Having a family doctor and number of OTC medicines on hand
Number of subjects: 3139
Study 16130888 — intervention group
Group type: EXPERIMENTAL
Intervention: Three or more kinds of OTC medicine
Number of subjects: 3139
Study 12133625 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-length tyrosinase protein vaccination
Number of subjects: 10
Study 10074992 — intervention group
Group type: EXPERIMENTAL
Intervention: Doulas
Number of subjects: 314
Study 10074992 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 314
Study 7580778 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide (CO2) as an insufflating gas
Number of subjects: 139
Study 7580778 — intervention group
Group type: COMPARATOR
Intervention: Conventional atmospheric air (AA)
Number of subjects: 139
Study 2142756 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuprophan membrane (CUP)
Number of subjects: 24
Study 2142756 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyacrylonitrile membrane (AN 69)
Number of subjects: 24
Study 2142756 — intervention group
Group type: COMPARATOR
Intervention: Both membranes (CUP and AN 69)
Number of subjects: 24
Study 7272675 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg i.v. preoperatively
Number of subjects: 196
Study 7272675 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg i.v. preoperatively
Number of subjects: 196
Study 7272675 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg i.v. postoperatively
Number of subjects: 196
Study 7272675 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg i.v. preoperatively and 200 mg i.v. daily for 3 days postoperatively
Number of subjects: 196
Study 31626831 — intervention group
Group type: EXPERIMENTAL
Intervention: Information designed to increase awareness of the risks of SSB consumption
Number of subjects: 430
Study 31626831 — intervention group
Group type: EXPERIMENTAL
Intervention: Information about SSB consumption norms
Number of subjects: 430
Study 31626831 — intervention group
Group type: EXPERIMENTAL
Intervention: Planning to reduce SSB consumption
Number of subjects: 430
Study 31626831 — intervention group
Group type: EXPERIMENTAL
Intervention: Risks information
Number of subjects: 430
Study 31626831 — intervention group
Group type: COMPARATOR
Intervention: Control information
Number of subjects: 430
Study 31626831 — intervention group
Group type: COMPARATOR
Intervention: No norms information
Number of subjects: 430
Study 31626831 — intervention group
Group type: COMPARATOR
Intervention: Control planning task
Number of subjects: 430
Study 29169877 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus carboplatin and paclitaxel with or without bevacizumab
Number of subjects: 1313
Study 29169877 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin and paclitaxel with or without bevacizumab (control group)
Number of subjects: 1313
Study 29169877 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab in EGFR FISH-positive squamous cell carcinoma
Number of subjects: 1313
Study 29169877 — intervention group
Group type: COMPARATOR
Intervention: Control group in EGFR FISH-positive squamous cell carcinoma
Number of subjects: 1313
Study 29169877 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab group adverse events
Number of subjects: 1313
Study 29169877 — intervention group
Group type: COMPARATOR
Intervention: Control group adverse events
Number of subjects: 1313
Study 27425785 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-Hz ipsilesional rTMS
Number of subjects: 69
Study 27425785 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-Hz contralesional rTMS
Number of subjects: 69
Study 27425785 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 69
Study 24445723 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil 40 mg + amlodipine 5 mg
Number of subjects: 566